Immutep Limited: Surging On Positive Head And Neck Data

Summary

• Immutep's eftilagimod shows promising results in head and neck cancer, with a median overall survival of 17.6 months, significantly higher than what has been observed with other approaches.
• IMMP is well-capitalized with $146.3 million in liquidity, ensuring operations can continue without imminent dilution and funding issues.
• Despite promising phase 2 data, the fate of eftilagimod remains uncertain, with future trials and FDA discussions critical for potential accelerated approval.
• The positive TACTI-003 readout strengthens my "Buy" sentiment, though risks remain in this challenging cancer treatment landscape.

miljko/E+ via Getty Images

Topline Summary and Update

Immutep Limited (IMMP, PRRUF) is an immunotherapy-focused biotech that I've covered recently, coming away with an optimistic take on their investment thesis built on pivoting fully into the development of a LAG3

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.